Sökning: onr:"swepub:oai:gup.ub.gu.se/55372" >
Long-term survival ...
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial
-
Stadler, R. (författare)
-
Luger, T. (författare)
-
Bieber, T. (författare)
-
visa fler...
-
Kohler, U. (författare)
-
Linse, R. (författare)
-
Technau, K. (författare)
-
Schubert, R. (författare)
-
Schroth, K. (författare)
-
Vakilzadeh, F. (författare)
-
Volkenandt, M. (författare)
-
Gollnick, H. (författare)
-
Von Eick, H. (författare)
-
- Bergh Thorén, Fredrik, 1976 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine
-
Strannegard, O. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009-07-08
- 2006
- Engelska.
-
Ingår i: Acta Oncol. - : Informa UK Limited. - 0284-186X. ; 45:4, s. 389-99
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- In a prospective, controlled, randomised, multicentre study 252 patients with totally resected cutaneous melanoma (248 in stage II-III and 4 in stage IV) were either treated with two doses of dacarbazine (DTIC) followed by a 6-month treatment with 3 MU thrice weekly of highly purified natural interferon-alpha (n = 128; arm A) or received no adjuvant treatment (n = 124; arm B). Treatment was well tolerated. After a median follow-up of 8.5 years ITT analysis showed that the difference in survival was statistically significant with respect to melanoma-related deaths (HR = 0.65, CI = 0.46-0.97, p = 0.022) and close to significance with respect to overall survival (HR 0.71, CI 0.49-1.00, p = 0.052). The risk reduction of melanoma-associated death, calculated by Cox proportional hazards modelling, after adjusting for identified predictive variables, was almost 50% (p = 0.002). The overall efficacy of the treatment appeared to be mainly attributable to effects observed in patients with deep and/or metastasizing tumours (HR 0.60, CI 0.40-0.90, p = 0.013).
Nyckelord
- Adult
- Aged
- Aged
- 80 and over
- Antineoplastic Combined Chemotherapy Protocols/ therapeutic use
- Chemotherapy
- Adjuvant
- Dacarbazine/administration & dosage
- Female
- Humans
- Interferon-alpha/administration & dosage
- Male
- Melanoma/drug therapy/ mortality
- Middle Aged
- Neoplasm Recurrence
- Local/drug therapy/mortality/secondary
- Neoplasm Staging
- Prospective Studies
- Skin Neoplasms/drug therapy/ mortality
- Survival Rate
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Stadler, R.
-
Luger, T.
-
Bieber, T.
-
Kohler, U.
-
Linse, R.
-
Technau, K.
-
visa fler...
-
Schubert, R.
-
Schroth, K.
-
Vakilzadeh, F.
-
Volkenandt, M.
-
Gollnick, H.
-
Von Eick, H.
-
Bergh Thorén, Fr ...
-
Strannegard, O.
-
visa färre...
- Artiklar i publikationen
-
Acta Oncol
-
Acta Oncologica
- Av lärosätet
-
Göteborgs universitet